Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor

Molecular Aspects of Medicine · Published 2025-11-10 · DOI 10.1016/j.mam.2025.101412

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.mam.2025.101412

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Advances in nano-delivery of natural products for cancer therapy: mechanisms and translational strategies · Biomedical Materials (Bristol) · 2026 · Cites or is cited by this article
• Serine metabolism in the central nervous system: advances and challenges on a conditionally essential amino acid · Molecular Aspects of Medicine · 2025 · Same journal
• The multifunctionality of the caspase family of proteases: A new perspective beyond cell death · Molecular Aspects of Medicine · 2025 · Same journal
• The potential use of anti-codon engineered tRNAs (ACE-tRNAs) to treat nonsense variants causing inherited retinal diseases · Molecular Aspects of Medicine · 2025 · Same journal
• Insulin resistance: The central node of convergence between unfolded protein response, diabetes, and cancer · Molecular Aspects of Medicine · 2026 · Same journal
• RNA editing of pathogenic variants causing inherited retinal diseases using endogenous ADAR-current and future perspectives · Molecular Aspects of Medicine · 2026 · Same journal
• Unveiling the P2X7 receptor: Exploring its mechanisms, pathogenic role in ocular diseases, and emerging therapeutic potential · Molecular Aspects of Medicine · 2025 · Same journal
• Molecular mechanism involved in sarcopenia and frailty, diagnosis and therapy · Molecular Aspects of Medicine · 2025 · Same journal
• Research advancements on sumoylation in gastrointestinal cancers · Molecular Aspects of Medicine · 2025 · Same journal
• The crosstalk of neutrophil extracellular trap-inflammasome and their roles in disease progression · Molecular Aspects of Medicine · 2025 · Same journal